SRR1429725
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.416
- KRAS_SIGNALING_DN+0.373
- ALLOGRAFT_REJECTION+0.303
- APICAL_SURFACE+0.253
- SPERMATOGENESIS+0.222
- INTERFERON_ALPHA_RESPONSE+0.216
- BILE_ACID_METABOLISM+0.179
- INFLAMMATORY_RESPONSE+0.179
- INTERFERON_GAMMA_RESPONSE+0.176
- MYOGENESIS+0.151
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.582
- MYC_TARGETS_V1-0.553
- MYC_TARGETS_V2-0.522
- UNFOLDED_PROTEIN_RESPONSE-0.508
- DNA_REPAIR-0.473
- PROTEIN_SECRETION-0.449
- MITOTIC_SPINDLE-0.429
- G2M_CHECKPOINT-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.418
- E2F_TARGETS-0.413
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1325927 | GTEX | — | 0.953 |
| 2 | SRR1313426 | GTEX | — | 0.941 |
| 3 | SRR1320916 | GTEX | — | 0.940 |
| 4 | SRR1421198 | GTEX | — | 0.939 |
| 5 | SRR1389348 | GTEX | — | 0.930 |
| 6 | SRR1341057 | GTEX | — | 0.930 |
| 7 | SRR1440962 | GTEX | — | 0.923 |
| 8 | SRR1352554 | GTEX | — | 0.919 |
| 9 | SRR1417202 | GTEX | — | 0.918 |
| 10 | SRR1331511 | GTEX | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.416 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.373 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.303 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.253 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.222 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.216 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.179 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.179 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.176 | Idelalisib | — uncovered |
| MYOGENESIS | 0.151 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.148 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.109 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.102 | Inavolisib | — uncovered |
| COAGULATION | 0.069 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.067 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.037 | Inavolisib | — uncovered |
| APOPTOSIS | 0.023 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.012 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.011 | Remibrutinib | — uncovered |